Revvity’s Signals MCP Connector Joins Claude, but RVTY Stays a Sleeper

Revvity’s Signals Software business joined Anthropic’s Model Context Protocol directory on July 1, putting the company’s governed scientific data behind Claude for the first time, including Claude Science, the AI workbench Anthropic launched a day earlier. The move turns Claude into a front end for Revvity’s R&D knowledge layer, and it lands nine days after Revvity put a Signals AI agentic framework inside its own Signals One platform.

The shift is small in revenue terms and loud in positioning terms. Revvity has $2.9 billion in 2025 revenue, roughly 11,000 employees, and customers in more than 160 countries, and the S&P 500 company is now placing a bet that scientists will want to query their organization’s experimental data through a chatbot instead of through prebuilt dashboards. Whether that bet pays off financially is a separate question from whether the stock market has decided it already has.

Signals AI was designed to help scientists transform connected R&D data into understanding, decisions and action. By joining Anthropic’s MCP ecosystem, we’re extending the reach of our Signals AI beyond our Signals One platform and enabling researchers to combine Claude’s reasoning capabilities with the governed data, ontology-driven scientific context and trusted knowledge managed across the entire Revvity Signals offering.

Kevin Willoe, president of Revvity Signals Software, said the integration in the July 1 announcement, distributed via Business Wire from Waltham, Massachusetts. The full release, headlined “Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration,” frames the connector as an extension, not a replacement, for the Signals AI capabilities Revvity had already shipped inside its own platform.

What the Signals MCP Connector Actually Does

Joining Anthropic’s MCP directory means Revvity now publishes a connector that any Claude user can call. When a scientist asks Claude a question about an experiment or a molecule, Claude can route the question to the Signals MCP connector, which sits in front of Revvity’s ontology-driven data layer and returns results grounded in the customer’s own governed scientific records. Revvity frames the layer as a way for scientists to “search, understand and act on complex R&D data using natural language” while keeping traceability and scientific precision, the same language the July 1 release uses to describe the partnership.

For scientists already working in Claude, the practical change is the kind of question they can ask. Anthropic’s Claude Science workbench shipped June 30 with more than 60 pre-configured life sciences skills and connectors, and now Revvity is one of those connectors. Researchers can pull in organizational knowledge, experimental data, and scientific context from Signals through natural-language conversations inside Claude rather than opening a separate Signals tab.

• Natural language access to governed R&D data, experimental context, and organizational knowledge from inside Claude and Claude Science
• Ontology-driven context grounded in Revvity’s domain ontologies and validated scientific algorithms, returning traceable responses rather than freeform model output
• Bidirectional scope: scientists who prefer Signals One keep the new Signals AI agentic framework, while scientists who prefer Claude can pull Signals data into the chat surface

The Two-Leg Software Pivot This Completes

The MCP connector is the second leg of a software rollout Revvity telegraphed ten days earlier. On June 22, Revvity announced “Signals AI, a Native Agentic Framework for Accelerating Scientific R&D,” built natively into Signals One. The June 22 release described an intelligence layer that lets scientists “engage directly with connected R&D knowledge and dynamically recast it for any purpose,” replacing the older model of prebuilt workflows and dashboards. The July 1 connector is the off-platform version of that same intelligence layer, exposing it through Claude rather than only through Signals One.

The framing matters because it positions Revvity’s software as the data substrate beneath any front end a scientist chooses. Anthropic’s Claude Science workflow bet framing argues that the moat in scientific AI sits in the workflow layer and the connectors around it, not in the underlying model. Revvity is now selling itself as one of those connectors, with governed scientific data and validated ontologies as the asset. The June 22 Signals AI launch and the July 1 MCP connector are not two separate products; they are the same data layer with two doors.

How RVTY Stock Reacted to the News

The stock did not move much. Revvity closed at $113.76 on July 2, the trading day after the MCP announcement, according to the company’s investor relations stock page, which also lists a 52-week high of $118.30 and a 52-week low of $81.22. Robinhood’s RVTY quote on July 3 showed the same $113.76 print, with an intraday range of $112.19 to $114.51. The market absorbed the announcement and moved on.

Analysts had been leaning slightly negative on RVTY heading into the news. MarketBeat’s aggregated 15-analyst twelve-month price target sits at $108.33, with a high of $120 and a low not shown in the snippet, below the current price. Simply Wall St’s analyst table shows the consensus target effectively flat at $113.73 against the same $113.76 share price. The MCP announcement did not push that consensus up in the days that followed.

• Share price (July 2 close): $113.76
• 52-week range: $81.22 to $118.30
• Analyst consensus 12-month target: $113.73 (Simply Wall St, 15 analysts)
• MarketBeat consensus 12-month target: $108.33 (15 analysts)

The Valuation the Software Story Has to Beat

RVTY trades at a premium earnings multiple that has already priced in some optimism about the software pivot. Simply Wall St’s valuation page pegs the stock at a 53.1x price-to-earnings ratio on earnings of US$239.11 million and a market cap of US$12.69 billion. The peer average across Icon, Bio-Techne, Qiagen, and Bio-Rad Laboratories sits at 61.2x, so RVTY is not extreme versus its closest peers, but it is well above the broader Global Life Sciences industry average of 37.1x. On the fair-PE metric that adjusts for forecast growth and margins, Simply Wall St estimates 25.2x, roughly half the current multiple.

The discounted cash flow model on the same valuation page puts future cash flow value at $143.90 per share, more than 20% above the current price, and labels the stock as trading “below future cash flow value.” That gap is the space where a software-led revenue ramp could live if it materializes, and it is also the space where a missed ramp would compress the multiple.

Why This Announcement Is a Sleeper, Not a Catalyst

The MCP connector fits a larger software pivot the market has not given Revvity credit for, and it does so without changing the structural setup. The Signals Software business, which Revvity says has more than three decades of installed base in scientific workflows, now has a distribution channel through Claude’s user base that it did not have nine days ago. A scientist who would never log into Signals One can still query Signals data through Claude Science, and the ontology layer is what they hit. That is a real distribution gain, and it lands on top of the recurring, higher-margin software revenue line that the bullish thesis on RVTY already leans on.

It is also a sleeper because the stock is paying for that thesis before the data shows up. The 53.1x current PE against a 25.2x fair PE means Revvity is being valued at roughly twice the multiple its own growth and margin profile would justify, and the consensus analyst target of $113.73 is essentially flat to the current price. The MCP connector adds optionality on adoption velocity, but the absence of a price move on July 1 says the market is treating optionality as already-priced optionality rather than new information.

The fair-value framing cuts the other way too. Simply Wall St’s DCF puts future cash flow value at $143.90, which would justify a higher share price if the software growth materializes, and the peer average PE of 61.2x shows RVTY is not extreme against its closest comparable companies. The announcement is a sleeper because both the bull and bear case can absorb it without breaking, and neither side has new evidence to push the other.

Where the Open Question Sits

Adoption velocity is the test that decides which side of that range RVTY lands on. The June 22 Signals AI release noted that “select capabilities of Signals AI are available today, with additional capabilities expected to be released and enhanced in the coming weeks,” and the July 1 MCP connector extends that same rollout into Claude’s user base. Anthropic’s Claude Science drug discovery expansion shows Anthropic pushing the same workbench into pre-clinical pipelines at the same time, which raises the ceiling on what a connector like Signals can plug into.

The MCP connector does not change Revvity’s near-term reliance on Signals software growth as the main catalyst, and it does not soften the diagnostics and instrumentation headwinds the company has carried into 2026. What it changes is the addressable surface area for Signals, because every Claude subscriber is now a potential Signals user without a separate login. The next quarter’s software revenue mix is the first real read on whether that surface area translates into bookings.

Frequently Asked Questions

What did Revvity announce with Anthropic on July 1, 2026?

Revvity’s Signals Software business joined Anthropic’s Model Context Protocol directory, publishing a connector that lets Claude and Claude Science access Signals AI capabilities and connected R&D data through a governed, ontology-driven intelligence layer. The July 1 release frames the connector as an extension of Signals AI beyond the Signals One platform rather than a separate product.

How is the Signals MCP connector different from Signals AI?

Signals AI is Revvity’s native agentic framework that lives inside Signals One and lets scientists query their data in natural language through that platform. The Signals MCP connector is the same data layer exposed as an MCP-compatible endpoint that Claude can call, so scientists who prefer Claude as their primary interface can still reach Signals data without opening Signals One.

Has RVTY stock moved on the Anthropic news?

Revvity closed at $113.76 on July 2, the trading day after the announcement, essentially unchanged from where it was trading before the release. The 52-week range sits between $81.22 and $118.30, and the 15-analyst consensus 12-month price target from Simply Wall St is $113.73.

Why is RVTY’s valuation under scrutiny even with this announcement?

Simply Wall St’s valuation page lists RVTY at a 53.1x PE ratio on $239.11 million of earnings, against a peer average of 61.2x and an industry average of 37.1x. The fair PE ratio on the same page is 25.2x, which is roughly half the current multiple, and that gap is what gives the software pivot both its upside and its risk.

What is Claude Science and why does it matter here?

Claude Science is Anthropic’s AI workbench for scientific research, launched June 30 with more than 60 pre-configured life sciences skills and connectors, including the new Signals connector from Revvity. It matters here because it is the specific Claude surface scientists will use to reach Signals data, and it is also the distribution surface Revvity is now betting on for Signals AI capabilities outside Signals One.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Stock valuations and analyst targets reflect snapshots as of publication and may change. AI and software revenue trajectories depend on adoption rates that are inherently uncertain. Consult a qualified financial professional before making investment decisions.